SEC EDGARJUN 111 min read$MCK

TYLER BRIAN S. sold $3.8M of MCK

TYLER BRIAN S. (Chief Executive Officer) sold 4,929 shares of MCKESSON CORP (MCK) at $763.00 ($3.76M total) on 2026-06-09 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · TYLER BRIAN S.

Published Jun 11, 2026, 2:30 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 11, 2026, 2:33 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$MCK

Neutral

medium confidence

Mentioned

$MCK

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$MCKNeutralLow

Why it matters

Traders may monitor insider activity as a sentiment input, but without any accompanying fundamental update, the signal is typically low-to-moderate and short-lived.

Market read

A scheduled CEO sale of ~$3.76M worth of McKesson shares was disclosed; absent other news, it is mainly a sentiment/positioning datapoint.

What to watch

The article provides only the sale size and post-transaction holdings; it does not disclose options, other concurrent insider trades, or any change in business outlook.

Relevance 5/10Novelty 8/10Timing: SEC Form 4 filed 2026-06-11 (sale dated 2026-06-09)

Background

The article is an SEC Form 4 insider transaction disclosure (CEO/direct holdings) sourced from EDGAR.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MCKNeutralMedium confidence

Context

McKesson CEO Tyler Brian S. filed an open-market sale of 4,929 shares on 2026-06-09 for ~$3.76M under a 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any effect is more sentiment/positioning than a new fundamental catalyst.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale with no accompanying company-specific news (earnings, guidance, deal, or regulatory action) in the article.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

Regional

None indicated; US-listed large-cap healthcare distribution name.

Global

None indicated; no cross-border transaction or global regulatory event mentioned.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than a bearish view.

Key entities

issuer
McKesson Corporation
Subject of the Form 4 insider transaction disclosure.
insider
Tyler Brian S.
CEO/director who sold shares in an open-market transaction under a 10b5-1 plan.

Read at source ← All news

SEP 15

$MCKMed

Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?

McKesson (MCK) raised its full-year EPS guidance to 13-15% (15-17% excluding prior-year items) and plans to rebrand its Medical-Surgical unit as Wellverse, targeting an IPO in 2H 2027. The company also aims to acquire Precision Medicine Group to expand oncology and biopharma services. Management highlights core operations are tracking ahead, but structural pressures on drug pricing and high leverage remain risks. McKesson projects $502.2B revenue and $6.3B earnings by 2029, implying 6.9% yearly

simplywall.st3 min

SEP 14

$MCKHigh

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

McKesson (MCK) raised its outlook, citing growth in its Oncology & Multispecialty segment, which saw 33% revenue growth and 41% adjusted operating profit growth in Q1. The company also announced a deal for Precision Medicine Group, expected to be strategically and financially accretive. McKesson's RxTS segment grew 9% in revenue and 13% in adjusted operating profit, with GLP-1-related business accounting for 11% of its revenue. The company plans to invest more in growth, automation, and technolo

yahoo.com2 min

SEP 8

$MCKMed

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson (MCK) plans a $2.25B precision medicine acquisition, expecting strategic alignment and value creation. Q1 revenue grew 5% in North American Pharmaceutical Distribution and 33% in Oncology. The company aims to return $5B to shareholders this year, including $2.5B in share repurchases and a 15% dividend increase. McKesson also expects to separate its Medical-Surgical business, rebranded as Wellverse, by late 2024.

yahoo.com6 min

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 6

$MCKMedAI 8/10

McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

McKesson (NYSE:MCK) to acquire Precision Medicine Group for $2.25B, expanding its oncology and specialty care business. The deal aims to enhance clinical research and commercialization services, with Precision Medicine joining McKesson's Oncology & Multispecialty segment. McKesson has been divesting non-core assets to fund such investments, and the Oncology segment saw 33% revenue growth in Q1 2026. However, the deal's timeline and integration risks remain uncertain.

yahoo.com3 min

SEP 5

$MCKHighAI 8/10

McKesson Stock: Is MCK Outperforming the Healthcare Sector?

McKesson (MCK), a $107.4B healthcare distributor, has outperformed the sector, rising 24.6% in 3 months and 33.4% in 52 weeks. Q1 2027 revenue hit $105.4B, up 7.7% YoY, with adjusted EPS of $9.93. The company raised full-year EPS guidance to $44.60. Analysts rate MCK a 'Strong Buy' with a $984.29 price target.